Opendata, web and dolomites

iSTantibody SIGNED

An innovative & seamless approach for the mass spectrometry analysis of monoclonal antibodies

Total Cost €


EC-Contrib. €






 iSTantibody project word cloud

Explore the words cloud of the iSTantibody project. It provides you a very rough idea of what is the project "iSTantibody" about.

forecasted    diseases    customers    eliminating    preparations    broad    gt    remarkable    kit    15    staff    german    multiplexed    patented    advantages    guarantee    standard    reproducible    istantibody    2026    preparation    companies    platforms    contaminants    time    tackles    easily    protocols    consists    effectiveness    possibility    significantly    young    proprietary    context    complicated    creation    purity    seize    shorten    jobs    biopharma    cagr    mabs    95    translates    innovation    final    ms    notably    employability    preomics    mass    manifold    spectrometry    characterised    patients    drawing    liquid    ist    tools    automated    innovative    purification    consumables    revenues    pharma    streamlined    scientific    13    12    poorly    pitfalls    sensitivity    benefit    performed    2022    scientists    safety    panel    skilled    million    handling    company    billion    perspectives    therapeutic    benefits    worldwide    consequent    consuming    antibodies    proteomics    date    technique    tight    revolutionise    portfolio    seeking    opening    volume    simplify    ahead    plugged    monoclonal    market    free   

Project "iSTantibody" data sheet

The following table provides information about the project.


Organization address
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PREOMICS GMBH DE (PLANEGG MARTINSRIED) coordinator 50˙000.00


 Project objective

Therapeutic monoclonal antibodies (mAbs) are innovative therapeutic tools that are currently drawing the attention of biopharma companies for their effectiveness against a broad panel of diseases. To guarantee safety for patients, tight control over the purity of mAbs preparations is crucial. The presence of contaminants in mAbs preparations can be assessed using mass spectrometry (MS), a technique characterised by remarkable sensitivity, but which requires a time-consuming, complicated and poorly reproducible sample preparation. Notably, at today’s date, this process cannot be automated or multiplexed: it has to be performed by highly skilled scientific staff, and - importantly - it cannot be easily “plugged in” the streamlined production approaches of pharma companies. PreOmics is a young German company seeking to revolutionise the MS proteomics market with its proprietary technology portfolio. Through the iSTantibody project, PreOmics translates its patented iST technology in the context of mAbs MS analysis and tackles the current pitfalls of mAbs sample preparation. Its final goal consists of a kit to simplify and shorten MS sample preparation by > 95% compared to standard protocols, eliminating the need for skilled scientists and allowing MS sample purification on automated liquid handling platforms. The advantages for potential customers are manifold – notably, significantly reduced costs, and the consequent possibility to free resources for mAbs development. The target sector of iSTantibody is the ever-growing market for MS sample preparation consumables, which is forecasted to reach a volume of € 1.3 billion worldwide in 2022, at a CAGR of 12%. The benefit of the iSTantibody project will produce remarkable benefits for PreOmics, both in terms of increased revenues ( € 15.3 million in 2026), employability (creation of 13 jobs) and innovation potential, opening new market perspectives and allowing PreOmics to seize more opportunities in the years ahead.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ISTANTIBODY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ISTANTIBODY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More  


Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More  

PhantoMinds (2019)

Better and faster innovations with PhantoMinds’ instant automated recruiting tool for open innovators

Read More